Dr. Alabi presents study results at EACR.
Dr. Adewumi Alabi (Consultant Clinical and Radiation Oncologist, NSIA-LUTH Cancer Center [NLCC]) recently traveled to Rotterdam, Netherlands to present her research during the European Association for Cancer Research (EACR) 2024 congress. Dr. Alabi’s poster, “Determining the Right Formula for Neoadjuvant Chemotherapy to Achieve Complete Pathologic Response in a Black Population: an Audit of Clinical Practice,” is a result of a research study led by Dr. Alabi and her colleagues from NLCC and the Lagos University Teaching Hospital (LUTH), Dr. Abdulrazzak Lawal, Dr. Bolanle Adegboyega, Dr. Adedayo Joseph, and Dr. Anthonia Sowunmi.
This research, which evaluated the treatment response in breast cancer patients with complete records receiving Neoadjuvant Chemotherapy care at NLCC and LUTH between 2011 and 2015, was made possible by an AC3T Study Pool grant awarded to Dr. Alabi. With the AC3T Study Pool funding, NLCC digitized its historical patient files, enabling not only Dr. Alabi’s study but other retrospective and ambidirectional cohort studies led by NLCC staff.
While in Rotterdam, Dr. Alabi also visited Erasmus Medical Center where she met with HypoAfrica collaborator, Prof. Luca Incrocci (Professor of Genito-Urinary Radiotherapy), who gave her a tour of Erasmus’ cancer facilities.